The following is a review of the literature and evidence supporting the anti-viral properties of 2-DG, lending further credence to
From PET scan results to molecular biology data, it has long been known that increased glucose metabolism is a common trait of cancerous cells. More recently, however, viral-infected cells have also been found to increase
We have been developing 2-deoxy-D-glucose (2-DG), an analog of glucose, as a non-toxic anti-cancer agent and in an FDA-approved Phase
Since 2-DG became available in Germany in 2018, The Lampidis Cancer Foundation has been actively collaborating with participating doctors and
Combining non-toxic glycolytic inhibitors with non-toxic antibiotics Although it has long been known that the anti-oxidant properties of vitamin C
In a recent publication titled 2-Deoxy-D-Glucose Inhibits Aggressive Triple-negative Breast Cancer Cells By Targeting Glycolysis And The Cancer Stem Cell Phenotype – a research group in Ireland, headed by Dr. Lorraine Driscoll, showed that triple-negative
As reported in September, the Lampidis Cancer Foundation, along with the MCS Foundation for Life, has been actively collaborating with
An article published in the British journal Nature last week reports the anti-cancer activity of the naturally found sugar mannose.
Dr. Lampidis Collaborates on Groundbreaking 2-DG Clinical Trial in Germany We are delighted to announce today that the Lampidis Cancer
A group of Students for 2-DG, led by Kimi Lampidis, daughter of renowned cancer researcher Dr. Theodore Lampidis, have recorded